

- 82 -

What is claimed is:

1. An antisense compound 8 to 30 nucleobases in length targeted to a nucleic acid molecule encoding human Jun N-terminal Kinase Kinase-1, wherein said antisense compound
5 specifically hybridizes with and inhibits the expression of human Jun N-terminal Kinase Kinase-1.

2. The antisense compound of claim 1 which is an antisense oligonucleotide.

3. The antisense compound of claim 2 wherein the
10 antisense oligonucleotide has a sequence comprising SEQ ID NO: 9, 10, 12, 13, 14, 15, 17, 19, 21, 23, 24, 25, 26, 28, 31, 32, 34, 36, 38, 40, 41, 42, 43, 8, 16, 22, 27, 29, 33, 35, 37, 45 or 46.

4. The antisense compound of claim 2 wherein the
15 antisense oligonucleotide has a sequence comprising SEQ ID NO: 9, 10, 12, 13, 14, 15, 19, 21, 23, 24, 25, 26, 28, 31, 32, 34, 36, 38, 41, 42 or 43.

5. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified
20 internucleoside linkage.

6. The antisense compound of claim 5 wherein the modified internucleoside linkage is a phosphorothioate linkage.

7. The antisense compound of claim 2 wherein the
25 antisense oligonucleotide comprises at least one modified sugar moiety.

8. The antisense compound of claim 7 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

9. The antisense compound of claim 2 wherein the
30 antisense oligonucleotide comprises at least one modified nucleobase.

10. The antisense compound of claim 9 wherein the modified nucleobase is a 5-methylcytosine.

-83-

11. The antisense compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

12. A composition comprising the antisense compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

13. The composition of claim 12 further comprising a
5 colloidal dispersion system.

14. The composition of claim 12 wherein the antisense compound is an antisense oligonucleotide.

15. A method of inhibiting the expression of Jun N-terminal Kinase Kinase-1 in human cells or tissues comprising
10 contacting said cells or tissues with the antisense compound of claim 1 so that expression of Jun N-terminal Kinase Kinase-1 is inhibited.

16. A method of treating a human having a disease or condition associated with Jun N-terminal Kinase Kinase-1
15 comprising administering to said animal a therapeutically or prophylactically effective amount of the antisense compound of claim 1 so that expression of Jun N-terminal Kinase Kinase-1 is inhibited.